rs7574865 — STAT4 Intron 3

STAT4 Intron 3 — The Interferon Amplifier

STAT4 (Signal Transducer and Activator of Transcription 4) is a transcription factor at the center of the type I interferon and IL-12 signaling network. When the immune system detects a threat, interferon-alpha and IL-12 bind receptors on T cells¹¹ interferon-alpha and IL-12 bind receptors on T cells
These cytokines activate JAK1/TYK2 and JAK2/TYK2 kinase pairs, which phosphorylate and activate STAT4, triggering STAT4 phosphorylation and nuclear translocation. STAT4 then activates genes driving Th1 differentiation, natural killer cell activation, and IFN-gamma production. The intronic variant rs7574865 in the third intron of STAT4 is the strongest common genetic risk factor for lupus²² strongest common genetic risk factor for lupus
rs7574865 T allele present on 31% of lupus chromosomes vs 22% of control chromosomes; OR 1.55, P=1.87×10⁻⁹ outside the HLA region — a distinction shared with only a handful of loci genome-wide.

The Mechanism

rs7574865 lies deep within intron 3 of STAT4, far from any coding sequence or known splice site. Precisely how it amplifies immune signaling remains under investigation, but the functional consequence is measurable: T allele carriers show significantly higher STAT4 mRNA and protein levels³³ significantly higher STAT4 mRNA and protein levels
Longitudinal study in early arthritis patients: TT genotype showed highest STAT4 protein by western blot; T allele independently associated with mRNA levels after adjusting for disease activity and glucocorticoids than GG homozygotes. The proposed mechanisms include altered transcription factor binding, changes to histone modification sites, or effects on a cryptic regulatory element within the large intron.

Whatever the upstream cause, the downstream effect is amplified. When T allele carriers encounter type I interferons or IL-12, STAT4 signaling is exaggerated⁴⁴ STAT4 signaling is exaggerated
Increased STAT4 expression produces stronger phosphorylation of STAT4 in response to IL-12 and IFN-alpha, amplifying downstream IFN-gamma production, driving excess IFN-gamma production. This dysregulated interferon response is a defining feature of systemic lupus erythematosus: the interferon signature — elevated expression of interferon-stimulated genes — is observed in roughly 75% of SLE patients and correlates with disease severity. STAT4 and IRF5 act additively⁵⁵ STAT4 and IRF5 act additively
Independent effects on SLE susceptibility through separate interferon pathway mechanisms to amplify this interferon dysregulation.

The Evidence

The STAT4 association with autoimmune disease was established in a landmark 2007 NEJM study by Remmers et al.⁶⁶ landmark 2007 NEJM study by Remmers et al.
multiple RA and SLE cohorts; rs7574865 T allele OR 1.32 for RA and OR 1.55 for SLE encompassing thousands of cases and controls. Homozygous TT individuals faced more than a doubled risk for lupus versus GG homozygotes, with a clear dose-response pattern — a genetic hallmark of additive inheritance.

The risk is not uniform across all lupus manifestations. A large phenotyping study⁷⁷ large phenotyping study
1,398 SLE patients sub-classified by ACR criteria; severe nephritis MAF 39.2% vs 22.5% in healthy controls; OR 2.35 for severe nephritis showed the T allele concentrates most strongly in severe nephritis (OR 2.35), anti-dsDNA antibody production (OR 1.86), and early-onset disease. The STAT4 locus also carries cerebrovascular risk: a study of 578 Swedish SLE patients⁸⁸ 578 Swedish SLE patients
Svenungsson et al. 2010; the LD-linked STAT4 variant rs10181656 showed OR 2.3 for ischemic stroke or TIA; risk comparable in magnitude to hypertension; associated with antiphospholipid antibody accumulation found that the LD-linked variant rs10181656 (which tags the same STAT4 risk haplotype) was associated with ischemic cerebrovascular events (OR 2.3), a magnitude comparable to classical vascular risk factors like hypertension. The proposed mechanism involves enhanced antiphospholipid antibody production — pro-thrombotic autoantibodies that promote clotting in blood vessels and the placenta.

Beyond lupus, rs7574865 has been replicated across multiple autoimmune conditions. For rheumatoid arthritis, meta-analyses confirm⁹⁹ meta-analyses confirm
Pooled OR 1.27 across 17 case-control studies (28 comparisons); consistent in European and Asian populations a pooled OR of approximately 1.27. Primary Sjögren's syndrome¹⁰¹⁰ Primary Sjögren's syndrome
124 Caucasian pSS patients vs 1,143 controls; T allele 29.6% in cases vs 22.3% in controls; P=0.01 also shows significant T allele enrichment. The breadth of associations is explained by STAT4's position as a master regulator of Th1 immunity — any condition driven by type I interferons or IL-12 is influenced by STAT4 dosage.

Pharmacogenomic Relevance

Because STAT4 functions downstream of JAK kinases — the very enzymes targeted by tofacitinib, baricitinib, and upadacitinib — the rs7574865 genotype has direct pharmacogenomic implications. A Phase 1 safety trial of tofacitinib in SLE¹¹¹¹ Phase 1 safety trial of tofacitinib in SLE
Double-blind placebo-controlled trial; subjects stratified by STAT4 rs7574865 genotype; T allele carriers showed greater NET complex reduction and more robust T cell activation marker suppression stratified participants by STAT4 genotype and found that T allele carriers showed greater reductions in circulating neutrophil extracellular trap (NET) complexes — a pro-inflammatory substrate elevated in lupus — and more robust suppression of T cell activation markers under tofacitinib treatment. Carriers of the T allele may derive greater benefit from JAK inhibitor therapy precisely because their STAT4-driven interferon amplification is the upstream driver of their disease activity.

Practical Actions

For GT heterozygotes, the ~30-50% elevated risk for SLE warrants awareness of the classic early symptoms — butterfly rash, photosensitivity, symmetric joint pain, serositis, fatigue — and low-threshold referral for antinuclear antibody (ANA) testing if these appear. TT homozygotes carry materially elevated risk for severe lupus nephritis (the STAT4 risk haplotype is also linked to ischemic cerebrovascular events via the LD-tagged variant rs10181656), and benefit from proactive baseline autoantibody testing even before symptoms develop. For patients already diagnosed with SLE or RA who carry the T allele, the JAK inhibitor class (tofacitinib, baricitinib, upadacitinib) directly targets the pathway amplified by this variant and may be particularly effective. Discuss genotype-informed treatment selection with a rheumatologist.

Interactions

The STAT4 rs7574865 T allele and the IRF5 rs10488631 T allele (rs10488631 is a tagging SNP in linkage disequilibrium with the primary IRF5 functional variants) both act within the type I interferon axis but through independent mechanisms. STAT4 amplifies the transcriptional response to interferon signaling; IRF5 amplifies interferon production upstream. Studies confirm their effects on SLE risk are additive rather than synergistic — each additional risk allele at either locus stacks independently onto overall risk. Individuals carrying risk alleles at both STAT4 (rs7574865) and IRF5 (rs10488631) face substantially higher composite SLE risk than either variant alone confers, and this combined burden is the basis for a proposed compound action. The combined recommendation: if you carry both STAT4 rs7574865(T) and IRF5 rs10488631(T) risk alleles, the interferon axis is doubly sensitized — prioritize ANA surveillance, minimize UV light exposure (a known interferon inducer in lupus), and if SLE is diagnosed, present the combined genotype to your rheumatologist as evidence for JAK inhibitor consideration. The companion SNP rs1270942 (CFB) participates in the same lupus genetic architecture through a distinct pathway (alternative complement pathway amplification and immune complex deposition) and can further stratify risk in the setting of renal involvement.